Clinical trial
The RECOVER IV Trial
NCT05506449 · Abiomed Inc., Industry · Terminated
Key facts
| NCT number | NCT05506449 |
|---|---|
| Title | The RECOVER IV Trial |
| Official title | Early Impella® Support in Patients With ST-Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock: The RECOVER IV Trial |
| Acronym | RECOVER IV |
| Lead sponsor | Abiomed Inc., Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | ST-segment Elevation Myocardial Infarction (STEMI), Cardiogenic Shock |
| Intervention type | Device, Other |
| Interventions | Impella CP®, Standard of Care |
| Enrollment | 4 |
| Start date | Oct 28, 2023 |
| Primary completion | May 10, 2024 |
| Completion | Dec 6, 2024 |
| First posted | Aug 18, 2022 |
| Last update posted | Jan 29, 2025 |
| Countries | Denmark, Germany, Switzerland, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: